Clinical Trial Update: Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating gemcitabine and cisplatin as first-line therapy for triple-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Platinol (cisplatin)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED